AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus pertuzumab reduced the ...

DHR and AstraZeneca team up to develop AI-powered diagnostics, aiming to boost precision medicine by improving patient ...

AstraZeneca on Sunday said its monoclonal antibody Imfinzi in combination with standard of care chemotherapy demonstrated significant and meaningful improvement in event-free survival in early stage ...

After rapid expansion, signs of a slowdown raise questions about future opportunities in the sector When it emerged that ...

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

An colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a bispecific antibody newly licensed by Pfizer.

A new pre-surgery treatment strategy for inherited breast cancer has achieved an astonishing 100% survival rate, thanks to a ...

Cambridge: AstraZeneca has announced that Imfinzi (durvalumab) has been recommended for approval in the European Union (EU) ...

The firm is the first Newcastle University spinout to secure investment from Northern Gritstone, a fund that has to date ...

Construction of AstraZeneca’s new global and R&D headquarters in Cambridge should have been completed last autumn – but builders are struggling to meet a revised deadline of May 2019.

Having already acquired UK-based Cambridge Antibody Technology in 2006, AstraZeneca merged these two companies to create a dedicated global biologics organisation known as MedImmune. Bestseller ...